Relmada Therapeutics (RLMD) Equity Average (2013 - 2026)
Relmada Therapeutics (RLMD) reported Equity Average of $152.6 million for Q1 2026, up 426.62% year-over-year from $29.0 million in Q1 2025, and up 218.04% on a QoQ basis from $48.0 million in Q4 2025.
Relmada Therapeutics (RLMD) has 14 years of Equity Average data on file, last reported at $152.6 million in Q1 2026.
- Quarterly Equity Average rose 426.62% year-over-year to $152.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.6 million (up 426.62% YoY) and the FY2025 annual result came in at $61.0 million, up 0.96% from the prior year.
- Equity Average improved to $152.6 million in Q1 2026 per RLMD's latest filing, from $48.0 million in the prior quarter.
- Across five years, Equity Average topped out at $209.3 million in Q1 2022 and bottomed at $12.7 million in Q3 2025.
- The 5-year median for Equity Average is $93.0 million (2023), against an average of $100.1 million.
- The widest annual swing landed in 2025, when Equity Average sank 76.71%; it then soared 426.62% in 2026.
- Tracing RLMD's Equity Average over 5 years: stood at $153.4 million in 2022, then slumped by 39.34% to $93.0 million in 2023, then slumped by 55.32% to $41.6 million in 2024, then gained by 15.43% to $48.0 million in 2025, then soared by 218.04% to $152.6 million in 2026.
- Per Business Quant, the three latest RLMD Equity Average figures stand at $152.6 million (Q1 2026), $48.0 million (Q4 2025), and $12.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.76 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 21.35 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.01 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.34 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 932.28 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 152.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152.62 Mn |
| Dec 31, 2025 | 47.99 Mn |
| Sep 30, 2025 | 12.71 Mn |
| Jun 30, 2025 | 19.19 Mn |
| Mar 31, 2025 | 28.98 Mn |
| Dec 31, 2024 | 41.57 Mn |
| Sep 30, 2024 | 54.56 Mn |
| Jun 30, 2024 | 66.77 Mn |
| Mar 31, 2024 | 78.70 Mn |
| Dec 31, 2023 | 93.04 Mn |
| Sep 30, 2023 | 106.03 Mn |
| Jun 30, 2023 | 118.40 Mn |
| Mar 31, 2023 | 132.95 Mn |
| Dec 31, 2022 | 153.39 Mn |
| Sep 30, 2022 | 181.60 Mn |
| Jun 30, 2022 | 203.62 Mn |
| Mar 31, 2022 | 209.33 Mn |
| Dec 31, 2021 | 140.48 Mn |
| Sep 30, 2021 | 84.77 Mn |
| Jun 30, 2021 | 94.00 Mn |
| Mar 31, 2021 | 98.36 Mn |
| Dec 31, 2020 | 113.90 Mn |
| Sep 30, 2020 | 127.22 Mn |
| Jun 30, 2020 | 122.70 Mn |
| Mar 31, 2020 | 114.42 Mn |
| Dec 31, 2019 | 60.83 Mn |
| Sep 30, 2019 | 6.80 Mn |
| Jun 30, 2019 | 4.04 Mn |
| Mar 31, 2019 | 954,289.50 |
| Dec 31, 2018 | -3.62 Mn |
| Sep 30, 2018 | -7.10 Mn |
| Jun 30, 2018 | -3.91 Mn |
| Mar 31, 2018 | -797,417.50 |
| Dec 31, 2017 | 1.09 Mn |
| Sep 30, 2017 | 1.46 Mn |
| Jun 30, 2017 | 2.13 Mn |
| Mar 31, 2017 | 3.74 Mn |
| Dec 31, 2016 | 5.12 Mn |
| Sep 30, 2016 | 6.31 Mn |
| Jun 30, 2016 | 8.62 Mn |
| Mar 31, 2016 | 10.98 Mn |
| Dec 31, 2015 | 12.80 Mn |
| Sep 30, 2015 | 11.32 Mn |
| Jun 30, 2015 | 5.65 Mn |
| Mar 31, 2015 | 3.54 Mn |
| Dec 31, 2014 | -8.06 Mn |
| Sep 30, 2014 | -10.92 Mn |
| Nov 30, 2013 | -20,844.00 |
| Aug 31, 2013 | -17,475.00 |
| May 31, 2013 | -11,550.50 |